MX2023003424A - Composiciones y metodos para inhibir la expresion genica. - Google Patents

Composiciones y metodos para inhibir la expresion genica.

Info

Publication number
MX2023003424A
MX2023003424A MX2023003424A MX2023003424A MX2023003424A MX 2023003424 A MX2023003424 A MX 2023003424A MX 2023003424 A MX2023003424 A MX 2023003424A MX 2023003424 A MX2023003424 A MX 2023003424A MX 2023003424 A MX2023003424 A MX 2023003424A
Authority
MX
Mexico
Prior art keywords
compositions
methods
gene expression
inhibiting gene
expression
Prior art date
Application number
MX2023003424A
Other languages
English (en)
Inventor
Jodi Michelle Kennedy
Jeremiah Dale Farelli
Original Assignee
Flagship Pioneering Innovations V Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations V Inc filed Critical Flagship Pioneering Innovations V Inc
Publication of MX2023003424A publication Critical patent/MX2023003424A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01043—Histone-lysine N-methyltransferase (2.1.1.43)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Abstract

La presente divulgación se refiere a represores de la expresión y a sistemas de represión de la expresión para modular la expresión de un gen diana en una célula.
MX2023003424A 2020-09-24 2021-09-24 Composiciones y metodos para inhibir la expresion genica. MX2023003424A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063082555P 2020-09-24 2020-09-24
US202163242957P 2021-09-10 2021-09-10
PCT/US2021/051945 WO2022067033A1 (en) 2020-09-24 2021-09-24 Compositions and methods for inhibiting gene expression

Publications (1)

Publication Number Publication Date
MX2023003424A true MX2023003424A (es) 2023-05-03

Family

ID=80845810

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003424A MX2023003424A (es) 2020-09-24 2021-09-24 Composiciones y metodos para inhibir la expresion genica.

Country Status (7)

Country Link
US (1) US20230399640A1 (es)
EP (1) EP4217477A1 (es)
JP (1) JP2023543218A (es)
KR (1) KR20230074525A (es)
AU (1) AU2021350024A1 (es)
MX (1) MX2023003424A (es)
WO (1) WO2022067033A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
CA3197423A1 (en) 2020-11-04 2022-05-12 Daniel Getts Engineered chimeric fusion protein compositions and methods of use thereof
WO2023057880A1 (en) * 2021-10-05 2023-04-13 Glaxosmithkline Intellectual Property Development Limited Crispr/cas9-based fusion proteins for modulating gene expression and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA038924B1 (ru) * 2012-05-25 2021-11-10 Те Риджентс Оф Те Юниверсити Оф Калифорния Способы и композиции рнк-специфической модификации днк-мишени и рнк-специфической модуляции транскрипции
WO2017031370A1 (en) * 2015-08-18 2017-02-23 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
US9896696B2 (en) * 2016-02-15 2018-02-20 Benson Hill Biosystems, Inc. Compositions and methods for modifying genomes
US20220380760A1 (en) * 2018-10-15 2022-12-01 Flagship Pioneering Innovations V, Inc. Disrupting genomic complex assembly in fusion genes
EP3918059A4 (en) * 2019-01-29 2022-11-30 Flagship Pioneering Innovations V, Inc. COMPOSITIONS CONTAINING AN ENDONUCLEASIS AND METHODS OF PURIFICATION OF AN ENDONUCLEASE

Also Published As

Publication number Publication date
US20230399640A1 (en) 2023-12-14
WO2022067033A1 (en) 2022-03-31
AU2021350024A1 (en) 2023-05-04
EP4217477A1 (en) 2023-08-02
AU2021350024A9 (en) 2023-07-13
KR20230074525A (ko) 2023-05-30
JP2023543218A (ja) 2023-10-13

Similar Documents

Publication Publication Date Title
MX2023003424A (es) Composiciones y metodos para inhibir la expresion genica.
MX2022010991A (es) Metodos y composiciones para modular un genoma.
AU2017261380A1 (en) Genetically engineered cells and methods of making the same
WO2018129404A8 (en) Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
MX2022001199A (es) Compuestos de urea, amida y heteroarilo sustituido para la inhibicion de cbl-b.
MX2018004263A (es) Edición genómica multiplexada.
MX2021012645A (es) Metodos y composiciones para editar acidos ribonucleicos (arn).
MX2017015400A (es) Inhibidores del mir-155 para tratar linfoma cutaneo de celulas t (ctcl).
WO2018097540A3 (ko) 무혈청면역세포배양용 배지첨가키트, 상기 키트를 이용한 면역세포배양방법, 상기 키트 또는 배양방법에 의해 얻어진 무혈청면역세포배양액 및 상기 배양액을 포함하는 화장료조성물
WO2020082046A3 (en) Compositions and methods for expressing factor ix
MX2018005692A (es) Limitación de trehalosa producida por levaduras en fermentación.
GB2458863A (en) Improved culture of stem cells
MX2019005476A (es) Ensayo de celulas madre pluripotentes.
PH12018502061A1 (en) Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
MX2018009247A (es) Uso de inhibidores de histona deacetilasa para aumentar las inmunoterapias.
WO2014088697A3 (en) Plant glutamine synthetase inhibitors and methods for their identification
PH12020552291A1 (en) System and methods for engineering bacteria fit for eukaryotic mrna production, export, and translation in a eukaryotic host
EP4218753A3 (en) Compounds for the reducing lipotoxic damage
MX2019009514A (es) Sustrato de lamina de acero inoxidable para separadores de celdas de combustible y metodo de produccion del mismo.
NZ738876A (en) Motile sperm domain containing protein 2 and inflammation
MX2022012829A (es) Metodo para tratamiento de medio antes de inoculacion.
MX2021011609A (es) Moduladores de interacciones de proteinas de superficie celular y metodos y composiciones relacionados con estos.
MX2021008022A (es) Proteínas heterodiméricas para modular células t gamma delta.
MX2020011470A (es) Metodos de terapia genica.